Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is a leader in the advanced wound care industry, with a diversified product portfolio that includes Apligraf, Dermagraft, and PuraPly. However, the company is facing reimbursement uncertainty due to changes made by CMS in 2026, resulting in a significant decline in revenue and profitability in the short term. Despite these challenges, Organogenesis has the potential to consolidate market share as smaller players exit, and its pipeline product ReNu could drive future revenue growth. We estimate the company's FY26 revenue to decline by ~29%, but see potential for normalized market conditions to drive higher numbers in the future. The company has a strong cash position and is well-positioned for future growth in the advanced wound care market.

Bears say

Organogenesis Holdings is facing many challenges that are negatively impacting its financial performance and stock outlook. These include a lower rev growth profile compared to its peers, disruptions in claims processing due to the new WISeR pilot program, uncertainties around CMS reimbursement policies, and new frictions in the market as providers navigate these changes. Additionally, the company has a negative free cash flow and a sizeable net loss projected for the next few years, leading to concerns about its financial stability. Collectively, these factors contribute to a negative outlook for Organogenesis Holdings' stock.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.